Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations

v3.7.0.1
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Operating Costs and Expenses:    
General and administrative $ 2,090 $ 2,426
Research and development 6,059 8,155
Total Operating Costs and Expenses 8,149 10,581
Loss from Operations (8,149) (10,581)
Other Income (Expense):    
Change in fair value of warrant liability 5,090 (498)
Interest income 1 1
Total Other Income (Expense) 5,091 (497)
Net Loss (3,058) (11,078)
Net Loss Attributable to Non-controlling Interest (212) (233)
Net Loss Attributable to Synthetic Biologics, Inc. and Subsidiaries $ (2,846) $ (10,845)
Net Loss Per Share - Basic and Dilutive $ (0.02) $ (0.12)
Weighted average number of shares outstanding during the period - Basic and Dilutive 117,447,260 90,826,752